Article Text

Download PDFPDF
The search for the tipping point on when to anticoagulate patients with atrial fibrillation

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Competing interests The author reports receiving consulting fees as member of the scientific advisory boards for Boehringer-Ingelheim, Bayer, Bristol-Myers Squibb-Pfizer, Daiichi-Sankyo and Cardiome and reports receiving lecture fees from these same companies.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles